# Beyond the injection: what responsible medical weight loss should look like in 2026 Canonical HTML source: [https://drluhard.com/insight-responsible-medical-weight-loss-2026.html](https://drluhard.com/insight-responsible-medical-weight-loss-2026.html) Author: Dr Luhard Jansen van Vuuren (Dr Luhard) Published: 1 August 2026 Last updated: 1 August 2026 The conversation around GLP-1 therapies has matured. The best question is no longer simply, “Which injection?” It is, “What complete medical strategy gives this patient the safest path to better long-term health?” Prescription treatment has changed what is medically possible for adults living with obesity. It has also created a marketplace full of shortcuts, oversimplified promises and products of uncertain provenance. Responsible care needs to separate clinical progress from commercial noise. ## Why this conversation matters now In December 2025, the World Health Organization issued its first global guideline on GLP-1 therapies for obesity. It recognises obesity as a complex, chronic and relapsing disease, and conditionally supports long-term GLP-1 treatment for appropriate adults as part of comprehensive care. The phrase *as part of comprehensive care* matters. The same guidance emphasises healthy nutrition, regular physical activity, professional support and long-term follow-up. Medicine may be powerful, but medicine alone is not the whole treatment plan. **Dr Luhard's clinical principle:** start with the patient, not the product. The prescription should follow the assessment—not replace it. ## 1. The right assessment comes before the right medicine A responsible consultation asks why weight has changed, which health risks are present and what has happened during previous attempts. Relevant medical conditions, current medication, appetite patterns, sleep, movement, previous surgery, family history and laboratory results may all change the decision. This is also where a doctor identifies reasons a specific treatment may be unsuitable, decides whether further investigation is needed and sets expectations that are medically realistic. A consultation should never be treated as an automatic route to a prescription. ## 2. Treatment should target health—not only the scale Weight is one measure. A useful plan also considers blood pressure, glucose control, lipid risk, liver health, sleep, mobility, symptoms, medication burden and body composition where appropriate. Nutrition and physical activity should be individualised and sustainable. The purpose is not a punitive diet or an exhausting programme; it is to support health, daily function and the quality of the change achieved. Where clinically appropriate, resistance activity and nutrition planning may also help preserve lean tissue during weight reduction. ## 3. Monitoring is part of the treatment—not an optional extra Follow-up creates the opportunity to review progress, side effects, adherence, symptoms and any change in medical risk. Depending on the individual, this may include blood pressure, body composition, blood investigations and review of other medication. Monitoring also prevents treatment from continuing on autopilot. If the balance between benefit, tolerance and risk changes, the plan should change with it. ## 4. The source and quality of medicine matter South African patients should be cautious about products promoted through social media or informal channels. SAHPRA has warned about falsified, substandard and unlawfully manufactured GLP-1 products and, in May 2026, announced joint enforcement action with the South African Pharmacy Council relating to unlawful manufacturing and distribution. Patients should understand what has been prescribed, where it is dispensed, how it should be stored, how to use it correctly and whom to contact if there is a concern. Regulation, prescription, traceability and product quality are patient-safety issues—not administrative details. ## 5. A long-term plan should exist before treatment begins Obesity is increasingly managed as a chronic disease rather than a short project. That means discussing duration, affordability, follow-up, changing health goals and what maintenance could look like from the beginning. The WHO describes GLP-1 therapies as generally long-term treatment and notes that evidence about long-term safety, maintenance and the effects of stopping continues to develop. A responsible doctor should be honest about what is known, what remains uncertain and how the plan will be reviewed over time. ## What a doctor-led consultation should give you - A clear review of your medical history, current treatment and relevant risks. - An explanation of whether prescription treatment is clinically appropriate. - A broader strategy that includes nutrition, activity, sleep and health monitoring. - Realistic expectations, known limitations and a plan for adverse effects. - A follow-up schedule and a conversation about maintenance. Dr Luhard provides adult medical weight loss consultations at Medify in Waterkloof, Pretoria. His approach combines clinical practice with the frameworks he teaches other doctors through MedBase: assess carefully, explain clearly, prescribe responsibly and monitor what matters. [Request an adult medical weight loss consultation](https://wa.me/27655595412) or [explore Dr Luhard's medical weight loss approach](https://drluhard.com/medical-weight-loss-pretoria.html). ## Sources and further reading - [World Health Organization: global guideline on GLP-1 medicines for obesity](https://www.who.int/news/item/01-12-2025-who-issues-global-guideline-on-the-use-of-glp-1-medicines-in-treating-obesity) - [World Health Organization: GLP-1 therapies—questions and answers](https://www.who.int/news-room/questions-and-answers/item/obesity-glp-1-therapies) - [SAHPRA and SAPC: May 2026 enforcement action on unlawful GLP-1/GIP medicines](https://www.sahpra.org.za/press-releases/sahpra-and-the-sapc-crack-down-on-unlawful-manufacturing-of-unregistered-glp-1-medicines/) - [SAHPRA: warning about GLP-1 products sold through social media](https://www.sahpra.org.za/news-and-updates/sahpra-warns-the-public-about-glp-1-products-sold-through-social-media-platforms/) This article provides general medical information and does not replace an individual consultation, diagnosis or prescription. Treatment suitability must be determined by a qualified medical practitioner.